Pulmonary arterial hypertension (PAH) is a rare, progressive, and potentially fatal cardiopulmonary syndrome that imposes a significant burden on patients in terms of morbidity and mortality. It is known that simultaneous targeting of multiple pathogenic pathways of PAH provides additive or synergistic clinical effects. The latest 2022 ESC/ERS PH Guidelines recommend that treatment strategy should be a risk-based, goal-orientated treatment approach, where achieving and/or maintaining a low-risk status is favorable and recommended.